2024
P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY
Idalsoaga F, Díaz L, Corsi O, Ayares G, Arnold J, Dunn W, Li Y, Singal A, Simonetto D, Ayala-Valverde M, Ramirez C, Morales-Arraez D, Zhang W, Qian S, Ahn J, Buryska S, Mehta H, Waleed M, Stefanescu H, Horhat A, Bumbu A, Attar B, Agrawal R, Cabezas J, Cuyàs B, Poca M, Pastor G, Sarin S, Maiwall R, Jalal P, La Tijera M, Kulkarni A, Rao N, Salazar P, Skladaný L, Bystrianska N, Prado V, Clemente-Sanchez A, Rincón D, Haider T, Chacko K, Romero G, Pollarsky F, Restrepo J, Toro L, Yaquich P, Mendizabal M, Garrido M, Marciano S, Dirchwolf M, Vargas V, Jimenez C, García-Tsao G, Ortiz G, Abraldes J, Kamath P, Shah V, Bataller R, Arab J. P-19 CHARACTERIZATION, PROGNOSTIC FACTORS, AND SURVIVAL IN MODERATE ALCOHOL-ASSOCIATED HEPATITIS: A MULTICENTER STUDY. Annals Of Hepatology 2024, 29: 101206. DOI: 10.1016/j.aohep.2023.101206.Peer-Reviewed Original ResearchRenal replacement therapyVariables associated with mortalityModerate AHAlcohol-associated hepatitisPrognostic factorsLiver transplantationMaddrey's discriminant functionAssociated with high mortalityMultiple organ failureRetrospective cohort studyMultivariate-adjusted modelsShort-term mortalityAssociated with mortalityCompeting-risks modelMedian ageCause of deathReplacement therapyMulticenter studyMELD scoreOrgan failureUnivariate analysisCohort studyFrequent causeSevere entitySurvival rate
2014
Prognostic Factors in Compensated and Decompensated Cirrhosis
Ripoll C, Zipprich A, Garcia-Tsao G. Prognostic Factors in Compensated and Decompensated Cirrhosis. Current Hepatology Reports 2014, 13: 171-179. DOI: 10.1007/s11901-014-0234-6.Peer-Reviewed Original ResearchHepatic venous pressure gradientPortal hypertensionPredictive factorsSignificant portal hypertensionSpecific predictive factorsVenous pressure gradientSerum albumin levelAlternative non-invasive methodDecompensated diseaseMELD scoreClinical decompensationFurther decompensationAlbumin levelsPrognostic factorsNon-invasive methodCirrhosisInvasive proceduresDecompensationDeathHypertensionNumber of studiesImportant predictorChildren's scoresRecent studiesScores
2010
Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis
Tandon P, Garcia–Tsao G. Renal Dysfunction Is the Most Important Independent Predictor of Mortality in Cirrhotic Patients With Spontaneous Bacterial Peritonitis. Clinical Gastroenterology And Hepatology 2010, 9: 260-265. PMID: 21145427, PMCID: PMC3713475, DOI: 10.1016/j.cgh.2010.11.038.Peer-Reviewed Original ResearchConceptsRenal dysfunctionCirrhotic patientsBacterial peritonitisAscitic fluid cell countHigh-risk patientsMain prognostic factorsNormal renal functionSpontaneous bacterial peritonitisHigh-risk groupImportant independent predictorBlood urea nitrogenGood quality studiesSBP resolutionVasoconstrictor therapyMELD scoreAdult patientsRenal functionIndependent predictorsMedian agePrognostic factorsRisk stratificationCommon infectionsImmunosuppressive factorsPrognostic valuePrognostic studies
1995
A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, McDonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia‐Tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double‐blind, placebo‐controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. PMID: 7657280, DOI: 10.1002/hep.1840220311.Peer-Reviewed Original ResearchConceptsPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisStratum 1Advanced primary biliary cirrhosisPlacebo-controlled trialBile acid poolLiver histologyPrognostic factorsTreatment failureSingle doseUrsodeoxycholic acidSevere symptomsPatientsUrsodiolLaboratory testsPlaceboHistologyBilirubinCirrhosisBiochemical testsGood responseStratum 3Acid poolLess effectA randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis
Combes B, Carithers R, Maddrey W, Lin D, Mcdonald M, Wheeler D, Eigenbrodt E, Muñoz S, Rubin R, Garcia-tsao G, Bonner G, West A, Boyer J, Luketic V, Shiffman M, Mills A, Peters M, White H, Zetterman R, Rossi S, Hofmann A, Markin R. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22: 759-766. DOI: 10.1016/0270-9139(95)90294-5.Peer-Reviewed Original ResearchPrimary biliary cirrhosisSerum bilirubinBiliary cirrhosisMajor complicationsStratum 1Liver diseaseTreatment failureAdvanced primary biliary cirrhosisPlacebo-treated patientsPlacebo-controlled trialBile acid poolStratum 3Advanced diseaseLiver histologyPrognostic factorsMilder diseaseSingle doseUrsodeoxycholic acidUrsodiolSevere symptomsPatientsPlaceboLaboratory testsComplicationsBilirubin